Clonal medicine targeting DNA damage response eradicates leukemia.

Autor: Toma MM; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Karami A; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Chirtala KN; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Pepek M; Department of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland., Hadzijusufovic E; Ludwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Department for Companion Animals & Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria., Stoklosa T; Department of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland., Valent P; Ludwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria., Skorski T; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA. tskorski@temple.edu.

Publikováno v: Leukemia [Leukemia] 2024 Mar; Vol. 38 (3), pp. 671-675. Date of Electronic Publication: 2024 Jan 16.